https://www.kainovatx.com/en/ 2026-04-03 daily 1.0 https://www.kainovatx.com/fr/ 2026-04-03 daily 1.0 https://www.kainovatx.com/en/press-releases/domain-therapeutics-doses-first-patients-in-phase-i-ii-trial-of-dt-7012-targeting-ccr8-in-solid-tumors/ 2026-02-02 weekly 0.7 https://www.kainovatx.com/en/team/sean-a-macdonald-2/ 2026-02-08 weekly 0.7 https://www.kainovatx.com/en/team/sean-a-macdonald-2/ 2026-03-27 weekly 0.7 https://www.kainovatx.com/en/media-room/citybiz-qa-with-sean-a-macdonald-chief-executive-officer-at-kainova-therapeutics/ 2026-03-27 weekly 0.7 https://www.kainovatx.com/en/media-room/citybiz-qa-with-sean-a-macdonald-chief-executive-officer-at-kainova-therapeutics/ 2026-01-28 weekly 0.7 https://www.kainovatx.com/en/press-releases/domain-therapeutics-doses-first-patients-in-phase-i-ii-trial-of-dt-7012-targeting-ccr8-in-solid-tumors/ 2026-02-02 weekly 0.7 https://www.kainovatx.com/en/press-releases/domain-therapeutics-appoints-boston-based-pharma-leader-jean-marie-cuillerot-m-d-as-chief-medical-officer/ 2026-02-02 weekly 0.7 https://www.kainovatx.com/en/press-releases/domain-therapeutics-rebrands-as-kainova-therapeutics-advancing-its-clinical-pipeline-of-gpcr-modulating-therapies/ 2026-02-09 weekly 0.7 https://www.kainovatx.com/en/media-room/jpm-2026-less-talk-and-more-action/ 2026-02-03 weekly 0.7 https://www.kainovatx.com/en/press-releases/domain-therapeutics-appoints-boston-based-pharma-leader-jean-marie-cuillerot-m-d-as-chief-medical-officer/ 2026-02-02 weekly 0.7 https://www.kainovatx.com/en/team/laurent-sabbagh/ 2026-03-27 weekly 0.7 https://www.kainovatx.com/en/team/antoine-italiano/ 2026-03-23 weekly 0.7 https://www.kainovatx.com/en/team/john-stagg/ 2026-03-27 weekly 0.7 https://www.kainovatx.com/en/team/michel-bouvier/ 2026-03-27 weekly 0.7 https://www.kainovatx.com/en/team/louis-etienne-fortier/ 2026-03-27 weekly 0.7 https://www.kainovatx.com/en/team/rosemary-mazanet/ 2026-03-27 weekly 0.7 https://www.kainovatx.com/en/team/james-huang/ 2026-03-27 weekly 0.7 https://www.kainovatx.com/en/media-room/base-to-base-biotech-podcast-with-sean-a-macdonald-ceo-at-kainova-therapeutics-gpcrs-and-beating-neurodegenerative-diseases/ 2026-03-10 weekly 0.7 https://www.kainovatx.com/en/publications/kainova-therapeutics-presented-clinical-and-preclinical-updates-on-its-gpcr-programs-at-aacr-annual-meeting-2026/ 2026-04-03 weekly 0.7 https://www.kainovatx.com/en/media-room/pharmaphorum-bio-europe-spring-2026-in-conversation-with-marjorie-sidhoum-vice-president-of-business-development-and-corporate-communications-at-kainova-therapeutics/ 2026-03-31 weekly 0.7 https://www.kainovatx.com/en/media-room/pharmaphorum-bio-europe-spring-2026-in-conversation-with-marjorie-sidhoum-vice-president-of-business-development-and-corporate-communications-at-kainova-therapeutics/ 2026-03-31 weekly 0.7 https://www.kainovatx.com/en/press-releases/kainova-therapeutics-to-present-clinical-and-preclinical-updates-on-its-gpcr-programs-at-aacr-annual-meeting-2026/ 2026-03-26 weekly 0.7 https://www.kainovatx.com/en/press-releases/kainova-therapeutics-to-present-clinical-and-preclinical-updates-on-its-gpcr-programs-at-aacr-annual-meeting-2026/ 2026-03-26 weekly 0.7 https://www.kainovatx.com/en/media-room/labiotech-beyond-biotech-podcast-with-sean-a-macdonald-ceo-of-kainova-therapeutics-reversing-tumor-immunosuppression-with-next-gen-gpcr-modulation/ 2026-03-27 weekly 0.7 https://www.kainovatx.com/en/media-room/labiotech-beyond-biotech-podcast-with-sean-a-macdonald-ceo-of-kainova-therapeutics-reversing-tumor-immunosuppression-with-next-gen-gpcr-modulation/ 2026-03-31 weekly 0.7 https://www.kainovatx.com/en/media-room/base-to-base-biotech-podcast-with-sean-a-macdonald-ceo-at-kainova-therapeutics-gpcrs-and-beating-neurodegenerative-diseases/ 2026-03-27 weekly 0.7 https://www.kainovatx.com/en/team/sylvie-ryckebusch/ 2026-03-27 weekly 0.7 https://www.kainovatx.com/en/press-releases/kainova-therapeutics-announces-positive-phase-i-results-for-dt-9081-an-oral-ep4-receptor-antagonist-in-advanced-solid-tumors/ 2026-03-10 weekly 0.7 https://www.kainovatx.com/en/press-releases/kainova-therapeutics-announces-positive-phase-i-results-for-dt-9081-an-oral-ep4-receptor-antagonist-in-advanced-solid-tumors/ 2026-03-10 weekly 0.7 https://www.kainovatx.com/en/media-room/podcast-featuring-jean-marie-cuillerot-chief-medical-officer-at-kainova-therapeutics-closing-the-gap-on-rare-diseases-in-2026/ 2026-03-27 weekly 0.7 https://www.kainovatx.com/en/media-room/podcast-featuring-jean-marie-cuillerot-chief-medical-officer-at-kainova-therapeutics-closing-the-gap-on-rare-diseases-in-2026/ 2026-03-03 weekly 0.7 https://www.kainovatx.com/en/press-releases/kainova-therapeutics-secures-32m-cad-to-accelerate-development-of-immuno-oncology-and-inflammation-therapies/ 2026-02-10 weekly 0.7 https://www.kainovatx.com/en/press-releases/kainova-therapeutics-secures-32m-cad-to-accelerate-development-of-immuno-oncology-and-inflammation-therapies/ 2026-02-10 weekly 0.7 https://www.kainovatx.com/en/media-room/jpm-2026-less-talk-and-more-action/ 2026-02-03 weekly 0.7 https://www.kainovatx.com/en/team/laurence-rulleau/ 2026-01-29 weekly 0.7 https://www.kainovatx.com/en/press-releases/domain-therapeutics-rebrands-as-kainova-therapeutics-advancing-its-clinical-pipeline-of-gpcr-modulating-therapies/ 2026-02-08 weekly 0.7 https://www.kainovatx.com/en/team/antoine-italiano/ 2026-03-23 weekly 0.7 https://www.kainovatx.com/en/team/john-stagg/ 2026-01-15 weekly 0.7 https://www.kainovatx.com/en/team/michel-bouvier/ 2026-01-10 weekly 0.7 https://www.kainovatx.com/en/team/sylvie-ryckebusch/ 2026-01-07 weekly 0.7 https://www.kainovatx.com/en/team/louis-etienne-fortier/ 2026-01-05 weekly 0.7 https://www.kainovatx.com/en/team/rosemary-mazanet/ 2026-01-29 weekly 0.7 https://www.kainovatx.com/en/team/james-huang/ 2026-01-07 weekly 0.7 https://www.kainovatx.com/en/team/aurelie-maisner/ 2026-03-27 weekly 0.7 https://www.kainovatx.com/en/team/aurelie-maisner/ 2026-01-07 weekly 0.7 https://www.kainovatx.com/en/team/marjorie-sidhoum/ 2026-01-10 weekly 0.7 https://www.kainovatx.com/en/team/nathalie-lenne/ 2026-01-10 weekly 0.7 https://www.kainovatx.com/en/team/stanislas-leonard-malmezat/ 2025-12-30 weekly 0.7 https://www.kainovatx.com/en/team/jean-marie-cuillerot/ 2026-02-08 weekly 0.7 https://www.kainovatx.com/en/team/stephan-schann/ 2026-02-08 weekly 0.7 https://www.kainovatx.com/en/team/sean-a-macdonald/ 2026-02-08 weekly 0.7 https://www.kainovatx.com/en/team/laurence-rulleau/ 2026-03-27 weekly 0.7 https://www.kainovatx.com/en/team/marjorie-sidhoum/ 2026-03-27 weekly 0.7 https://www.kainovatx.com/en/team/laurent-sabbagh/ 2026-01-10 weekly 0.7 https://www.kainovatx.com/en/team/sean-a-macdonald/ 2026-03-27 weekly 0.7 https://www.kainovatx.com/en/team/nathalie-lenne/ 2026-03-27 weekly 0.7 https://www.kainovatx.com/en/team/stanislas-leonard-malmezat/ 2026-03-27 weekly 0.7 https://www.kainovatx.com/en/team/jean-marie-cuillerot/ 2026-03-27 weekly 0.7 https://www.kainovatx.com/en/team/stephan-schann/ 2026-03-27 weekly 0.7 https://www.kainovatx.com/en/privacy-policy/ 2026-02-11 weekly 0.7 https://www.kainovatx.com/en/ 2026-04-03 weekly 0.7 https://www.kainovatx.com/en/newsroom/all/ 2026-01-09 weekly 0.7 https://www.kainovatx.com/en/newsroom/all/ 2025-12-30 weekly 0.7 https://www.kainovatx.com/en/newsroom/all/ 2026-01-11 weekly 0.7 https://www.kainovatx.com/en/newsroom/press-release/ 2026-01-09 weekly 0.7 https://www.kainovatx.com/en/newsroom/all/ 2025-12-30 weekly 0.7 https://www.kainovatx.com/en/newsroom/press-release/ 2025-12-30 weekly 0.7 https://www.kainovatx.com/en/terms-of-use/ 2026-01-20 weekly 0.7 https://www.kainovatx.com/en/newsroom/in-the-media/ 2026-01-09 weekly 0.7 https://www.kainovatx.com/en/newsroom/in-the-media/ 2026-01-27 weekly 0.7 https://www.kainovatx.com/en/privacy-policy/ 2026-02-11 weekly 0.7 https://www.kainovatx.com/en/?page_id=63 2026-01-09 weekly 0.7 https://www.kainovatx.com/en/terms-of-use/ 2026-01-20 weekly 0.7 https://www.kainovatx.com/en/ 2026-03-31 weekly 0.7